Abstract
In order to study the relationship between circulating levels of CA 15-3 and the disease extent in predicting survival, we prospectively followed 312 breast cancer (BC) patients, from October 1988 to March 1995, from the time of first relapse. CA 15-3 values were assessed before treatment onset. Disease extent was defined as the percentage of liver or lung involvement and the number of bone segments positive at scintigraphy. The covariates were primary tumour characteristics (T, N and hormone receptor status) and patient characteristics at recurrence (menopause, performance status and age). Higher CA 15-3 serum levels were found in patients with visceral metastases or with pleural effusion. A logistic regression model selected disease extent in liver, lung and bone as independent variables for the determination of abnormal CA 15-3 values. Univariate survival analysis confirmed the positive prognostic influence of low CA 15-3 serum levels, absence of visceral metastases and the presence of only one metastatic site. Multivariate Cox's survival analysis selected disease extent in liver, lung, bone and soft tissue but not level of CA 15-3 as prognostic factors. In conclusion, CA 15-3 is not an independent variable in determining survival, its prognostic role being linked to the disease extent. This association suggests that CA 15-3 may be useful in assessing disease extent when this is not easily assessable.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tampellini, M., Berruti, A., Gerbino, A. et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 75, 698–702 (1997). https://doi.org/10.1038/bjc.1997.124
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.124
This article is cited by
-
Clinical impact of removing respiratory motion during liver SABR
Radiation Oncology (2019)
-
Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes
World Journal of Surgical Oncology (2018)
-
Sublingual Nodules: Diagnostic Markers of Metastatic Breast Cancer
Chinese Journal of Integrative Medicine (2018)
-
Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes
Clinical & Experimental Metastasis (2016)
-
Curative-intent stereotactic body radiation therapy for residual breast cancer liver metastasis after systemic chemotherapy
Breast Cancer (2014)